ライフサイエンスコーパス: blood transfusion

1 , central line, intracranial hemorrhage, and blood transfusion).

2 high serum ERFE levels, which decrease after blood transfusion.

3 ad grade IV thrombocytopenia but required no blood transfusion.

4 disease (TA-GVHD) is a rare complication of blood transfusion.

5 typing of blood groups is essential prior to blood transfusion.

6 understanding the risk of prion infection by blood transfusion.

7 required erythropoietin; no patient required blood transfusion.

8 ion against transmission of prion disease by blood transfusion.

9 re similar in age, injury severity, and 24hr blood transfusion.

10 at preventing transmission of the disease by blood transfusion.

11 ough previous transplantation, pregnancy, or blood transfusion.

12 Most (79%) required blood transfusion.

13 in the development of lung injury following blood transfusion.

14 ction in this population are breast milk and blood transfusion.

15 ne of the leading causes of death related to blood transfusion.

16 ital with capacity for emergency surgery and blood transfusion.

17 gastrointestinal tract, 26 of whom required blood transfusion.

18 , heart, lung, and stem-cell transplant, and blood transfusion.

19 -deficient children; 13/119 (10.9%) required blood transfusion.

20 cesarean section requires donor (allogeneic) blood transfusion.

21 eding requiring treatment and postprocedural blood transfusion.

22 tion, erythropoiesis-stimulating agents, and blood transfusion.

23 ng the higher (7 d) primaquine dose required blood transfusion.

24 tion, physical status, emergency status, and blood transfusion.

25 .90 to -5.20 g/dL); 1 in 200 (0.5%) required blood transfusion.

26 ermine the main predictors of intraoperative blood transfusion.

27 a donor and an intended recipient prior to a blood transfusion.

28 surements: Patients were followed from first blood transfusion.

29 Patients were followed from first blood transfusion.

30 Initial postoperative blood transfusion.

31 , and is confounded by potential concomitant blood transfusion.

32 ient with ribavirin-related anemia requiring blood transfusion.

33 all preprocedure hemoglobin levels versus no blood transfusion.

34 ts (27.5%) received at least 1 postoperative blood transfusion.

35 243 (4.6%) patients received a postoperative blood transfusion.

36 ocytic leukemia (CLL) is transmitted through blood transfusions.

37 avenous fluids, vasopressors, inotropes, and blood transfusions.

38 Overall, 217 patients (54.1%) received blood transfusions.

39 high-risk blunt trauma patients who received blood transfusions.

40 I may be improved by more restrictive use of blood transfusions.

41 ine of incurable diseases, immunotherapy and blood transfusions.

42 and halt transmission of these pathogens via blood transfusions.

43 emia with infections and was managed without blood transfusions.

44 timated blood loss, fluid resuscitation, and blood transfusions.

45 opathy in cardiac surgery and thereby reduce blood transfusions.

46 ent Intervention Triage) and requirement for blood transfusions.

47 transfusion, and estimated cost of excessive blood transfusions.

48 vs. 319.3 min, P<0.001), a greater need for blood transfusions (0.1 vs. 1.6 units, P<0.001) and plas

49 d no difference in the rate of perioperative blood transfusion (1 patient [2%] for LH vs 5 [10%] for

50 No significant difference was seen with blood transfusion (10.4% versus 10.8%; P=0.70), gastroin

51 =0.62), acute rejection (8% vs. 6%, P=0.68), blood transfusions (10% vs. 18%, P=0.24), and severe gas

52 implantation (2.9% versus 8.0%; P<0.001) and blood transfusion (12.8% versus 22.9%; P<0.001).

53 uded plasmapheresis (18), chemotherapy (30), blood transfusions (2), transplantation of progenitor he

54 Patients with anemia received >/=1 blood transfusion 2x more often, but the indication of t

55 ey injury (20.8% vs 13.8%, P < .001), 30-day blood transfusion (3.4% vs 2.7%, P < .01), and 1-year re

56 major bleeding (14.0% versus 0.9%; P<0.001), blood transfusion (3.7% versus 0.2%; P<0.001), and death

57 anemia (3.2% compared with 16.4%; P < 0.05), blood transfusion (4.5% compared with 16.4%; P < 0.05),

58 0.007), and a higher need for postoperative blood transfusion (4/14 vs 2/30, P = 0.071).

59 ; HR: 1.00; 95% CI: 0.50 to 1.99; p = 0.99), blood transfusions (4.8% vs. 4.5%; HR: 1.09; 95% CI: 0.5

60 7]; P < .001), and casualties who received a blood transfusion (50.2% [618 of 1231] vs 3.7% [121 of 3

61 for those critically injured who received a blood transfusion (6.8% [40 of 589] vs 51.0% [249 of 488

62 associated with a greater risk of requiring blood transfusion (7 studies in cardiac surgery, totalin

63 jor bleeding (15.3% versus 55.6%; P<0.0001), blood transfusions (9.2% versus 43.2%; P<0.0001), and ac

64 extremity amputation (80%) and large volume blood transfusion (97.2%).

65 of betaT is a lifelong dependence on regular blood transfusions, a consequence of which is systemic i

66 ses the risk of blood transfusion allogeneic blood transfusion (ABT).

67 d other refractory anemias requiring regular blood transfusions accumulate iron that damages the live

68 of this study was to examine variability in blood transfusions across hospitals and the relationship

69 ver if left untreated, increases the risk of blood transfusion allogeneic blood transfusion (ABT).

70 ith a significant decreased risk of post-PCI blood transfusion among higher volume r-PCI sites.

71 tween hospital-level rates of intraoperative blood transfusion and 30-day mortality among older patie

72 lucidate in more detail the relation between blood transfusion and AKI and its effects on short- and

73 After adjusting for cofactors such as blood transfusion and allograft nephrectomy, prolonged i

74 s with severe sepsis, and was increased with blood transfusion and among nonsurvivors of sepsis.

75 Blood transfusion and breast milk feeding.

76 dt-Jakob disease (vCJD) has occurred through blood transfusion and could also theoretically occur as

77 ditive effect with those who both received a blood transfusion and developed sepsis having even worse

78 cross hospitals and the relationship between blood transfusion and in-hospital mortality in a large,

79 ll largely dependent on supportive care with blood transfusion and iron chelation.

80 In a large study population, blood transfusion and mechanical ventilation were the on

81 ly, RARP led to a lower risk of experiencing blood transfusion and of having a pLOS (all P < .001).

82 the disease may also be transmitted through blood transfusion and perinatally.

83 Perioperative blood transfusion and postoperative morbidity are indepe

84 nvestigate the potential additive effects of blood transfusion and sepsis on colon cancer disease-spe

85 In addition to blood transfusion and sexual transmission, HTLV-1 is tra

86 that the world's first centralized national blood transfusion and storage service was being establis

87 y outcomes were (1) receipt of perioperative blood transfusions and (2) need for reoperation for reas

88 hough RARP was associated with lower risk of blood transfusions and a slightly shorter length of stay

89 nd 1991 to compare the effects of allogeneic blood transfusions and an autologous blood transfusion p

90 In addition to repeated blood transfusions and increased iron absorption, chroni

91 yndrome of respiratory distress triggered by blood transfusions and is the leading cause of transfusi

92 directed hemodynamic therapy, and minimizing blood transfusion), and treatment (early initiation of r

93 quired HCV through either injecting drugs or blood transfusion, and (3) an estimated date of acquirin

94 on rates, 30-day acute kidney injury, 30-day blood transfusion, and 1-year readmission rates for myoc

95 Because of covariation, blood loss, blood transfusion, and complications were tested in sepa

96 Safety outcomes included major bleeding, blood transfusion, and hospitalization for bleeding.

97 f perioperative IV iron reduces the need for blood transfusion, and is associated with a shorter hosp

98 ine the association between PCI access site, blood transfusion, and mortality.

99 spital stay and rates of pancreatic fistula, blood transfusion, and readmission were not statisticall

100 reactions, 3 had minor bleeding, 6 required blood transfusions, and 3 had life-threatening bleeding.

101 For ongoing therapies, hemodialysis, blood transfusions, and antibiotics were more likely to

102 ational databases suggest that a restrictive blood transfusion approach is being increasingly impleme

103 ren with severe anemia and their response to blood transfusion are limited.

104 Perioperative blood transfusions are associated with infectious compli

105 Perioperative blood transfusions are associated with shorter survival,

106 No consensus exists on whether preoperative blood transfusions are beneficial in patients with sickl

107 esection in patients receiving perioperative blood transfusions are caused by the clinical circumstan

108 Blood transfusions are critically important in many medi

109 Blood transfusions are frequently given to patients with

110 Blood transfusions are generally avoided for potential r

111 , as the potentially harmful consequences of blood transfusions are increasingly being recognized, ef

112 Repeated blood transfusions are one of the major causes of iron o

113 Blood transfusions are the mainstay of stroke prevention

114 difying therapies, hydroxyurea and long-term blood transfusions, are available but underused.

115 ial infections and sepsis, and the amount of blood transfusion as source of free heme correlated with

116 The overall reduction observed in donor blood transfusion associated with the routine use of cel

117 support were similar among those assigned to blood transfusion at a higher hemoglobin threshold and t

118 r hemoglobin threshold and those assigned to blood transfusion at a lower threshold; the latter group

119 n, antithymocyte globulin induction therapy, blood transfusion at the transplantation procedure, high

120 Injection drug use and blood transfusion before 1990 are dominant risk factors

121 , C-reactive protein, smoking, drinking, and blood transfusion before 1992.

122 (including injection drugs) and receipt of a blood transfusion before 1992; 49% of persons with HCV i

123 ection is unknown, posing risk to others via blood transfusion, blood products, organ or tissue graft

124 The number of blood transfusions but not the indication of transfusion

125 mitted with severe anaemia needing an urgent blood transfusion, but blood is often unavailable.

126 e III cancer, lymphovascular permeation, and blood transfusion, but not the operative approach, were

127 Blood transfusion can be a lifesaving treatment for the

128 anial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary strok

129 Sequential expansion of blood transfusion capability after 2012 to deployed mili

130 ess to HLA typed blood is achievable as many blood transfusion centers recruit donors for stem cell d

131 and more frequently required critical care, blood transfusion, central line placement, mechanical ve

132 sepsis (chi (2) = 7.47; P = 0.006), multiple blood transfusions (chi (2) = 5.11; P = 0.02), and deliv

133 ickle cell anemia or thalassemia, history of blood transfusion, cocaine and other drug use; there was

134 roved in the anemic animals undergoing fresh blood transfusion compared to control anemic animals.

135 The presence of Aspergillus antigens in blood transfusion components from different manufacturer

136 ion of intravenous fluids, vasopressors, and blood transfusion decreases mortality among Zambian adul

137 Liberal blood transfusion did not affect mortality compared with

138 tal treatment with mechanical ventilation or blood transfusion did not cause the observed increase in

139 The stored blood transfusion did not result in significant changes

140 sion (HR: 1.02, 95% CI: 0.65-1.58, P=0.970), blood transfusions did not increase the risk of overall

141 rates the lack of XMRV transmission by whole-blood transfusion during the acute phase of infection.

142 nalyses on 39 patients who did not receive a blood transfusion during the study period, the baseline

143 ing episodes and were more likely to receive blood transfusions during an episode.

144 s or pneumonia, more frequently had received blood transfusions during surgery, and received ventilat

145 and decreases the need for vasopressors and blood transfusions during the neonatal period.

146 te form having vastly improved with exchange blood transfusion (EBT).

147 of various management strategies, including blood transfusion, erythropoietin, blood substitutes, ir

148 Hospital-level rates of intraoperative blood transfusion for older surgical patients with signi

149 alassemia intermedia, which does not require blood transfusion for survival, hyperabsorption of iron

150 rary practice, a trend of less perioperative blood transfusions for oncologic abdominal surgery was o

151 1998 demonstrating the efficacy of long-term blood transfusions for primary stroke prevention.

152 re are still occasions when patients require blood transfusions for reasons such as resistance to ery

153 ing mean arterial pressure (>/=65 mm Hg) and blood transfusion (for patients with a hemoglobin level

154 (such as aspiration, repeat misoprostol, and blood transfusion), frequency of continuing pregnancy, r

155 and Parkinson disease in patients receiving blood transfusions from donors who were later diagnosed

156 nts with sickle cell disease (SCD) receiving blood transfusions from ethnically matched donors.

157 Secondary outcomes included infections, blood transfusions, gastrointestinal side-effects, and a

158 A history of blood transfusion gave a relative risk of 4.1 of develop

159 Patients who received allogeneic blood transfusions had a higher incidence of nosocomial

160 Blood transfusion has been identified as a source of hum

161 Perioperative blood transfusion has been reported to have a negative i

162 variant Creutzfeldt-Jakob disease (vCJD) via blood transfusion have relied largely on data from roden

163 associated with a decreased risk of post-PCI blood transfusion (hazard ratio, 0.4; 95% confidence int

164 24 h after delivery; death; requirement for blood transfusion; hemoglobin changes; and use of additi

165 lar complications occurred in 7.0% of cases, blood transfusion in 17.5%, clinical stroke in 1.8%, and

166 saturation [tSo2]) before, during, and after blood transfusion in a cohort of children presenting to

167 as to assess the safety and efficacy of cord blood transfusion in children with severe anaemia.

168 The majority of patients undergoing blood transfusion in clinical practice cannot be matched

169 XMRV transmission was evaluated by whole-blood transfusion in rhesus macaques.

170 od products, the immunomodulatory effects of blood transfusion in this group are inadequately describ

171 ients, the use of erythropoietin in 54%, and blood transfusions in 12%.

172 were documented frequently (eg, more than 6 blood transfusions in 20% of all patients and relaparoto

173 the decision-making regarding perioperative blood transfusions in patients undergoing curative recta

174 mias other than TM that may require multiple blood transfusions, including sickle cell anemia and mye

175 cell anaemia (n = 27) not receiving monthly blood transfusions (interquartile range cerebral blood f

176 Operation duration, blood transfusion, intubation duration, and hospital sta

177 01270854) of adult trauma patients requiring blood transfusion, intubation, or operation within 60 mi

178 Most required regular blood transfusion, iron chelation, and intravenous immun

179 Blood transfusion is associated with a significant risk

180 Blood transfusion is associated with acute kidney injury

181 Blood transfusion is commonly used in surgical procedure

182 Blood transfusion is controversial for anemic patients w

183 Blood transfusion is one of the most common procedures i

184 Blood transfusion is strongly associated with AKI in pat

185 untries, RCTs have demonstrated that regular blood transfusion is the optimal current therapy for sec

186 parasite that can be transmitted by means of blood transfusion, is responsible for the majority of ca

187 a that develops during or within 6 h after a blood transfusion, is the most frequent cause of transfu

188 hese findings do not support hypotheses that blood transfusion leads to long-term immunosuppression t

189 mong the 5334 patients without postoperative blood transfusion, lower nadir hematocrit was associated

190 The number of units of blood transfusion </=24 hours was the strongest predicto

191 Perioperative blood transfusions may adversely affect survival in pati

192 nefits of r-PCI in terms of reduced post-PCI blood transfusions may be more pronounced at sites that

193 The restrictive group received fewer blood transfusions: mean 20.3 +/- 32.7 units, median = 8

194 Blood transfusion might affect long-term mortality by ch

195 laria chemotherapy, fluid support, and whole-blood transfusion, mimicking the standard of care for th

196 Whether perioperative blood transfusions negatively impact survival remains a

197 ies had an adjusted odds ratio for receiving blood transfusion of 1.93 (95% CI, 1.21-3.07) compared w

198 identified, of whom 5900 (30.0%) received a blood transfusion (of 13657 patients who underwent a pan

199 be probably or certainly caused by the cord blood transfusion (one-sided 97.5% CI 0-6.5).

200 ificant bleeding, including any preoperative blood transfusion or transfusion of greater than 4 units

201 morbidity (odds ratio (OR) 0.73, P = 0.028), blood transfusion (OR 0.44, P = 0.001), and LOS (P = 0.0

202 1.44, 95% CI 1.09-1.91), and intraoperative blood transfusion (OR 1.45, 95% CI 1.15-1.83) were weak

203 nasogastric tube (OR = 1.6), intraoperative blood transfusion (OR = 1.7), diabetes mellitus (OR = 2.

204 t risk factors for pneumonia: intraoperative blood transfusion (OR = 1.9), diabetes mellitus (OR = 2.

205 46; 95% CI, .33-.66; P < .01) and history of blood transfusion (OR, 0.43; 95% CI, .22-.83; P = .01) w

206 ence interval [CI], 1.99-4.08; P < 0.01) and blood transfusion (OR, 1.97; 95% CI, 1.20-3.14; P = 0.01

207 who repeatedly denied injection drug use or blood transfusion (OR, 8.5; P < .0001).

208 drug use (odds ratio [OR], 35.0; P < .0001), blood transfusion (OR, 9.9; P < .0001), and intranasal c

209 rdial complications, hematoma or hemorrhage, blood transfusion, or cardiogenic shock.

210 percent of patients required erythropoietin, blood transfusions, or RBV dose reduction for anemia.

211 us catheter, administration of inotropes, or blood transfusions; or usual care.

212 ienced similar amount of blood loss, rate of blood transfusions, overall and major morbidity, and 30-

213 pic DN decreased the need for intraoperative blood transfusion (P < 0.001) and reduced the incidence

214 enal failure requiring dialysis (P < 0.001), blood transfusion (P < 0.001), electrolyte disturbance (

215 were the Rockall score (p = 0.004), units of blood transfusion (p = 0.031), and no antibiotic prophyl

216 e, hepatic iron overload because of frequent blood transfusions; P<0.05 for both), whereas diastolic

217 We sought to quantify the risk of blood transfusion per se in male renal patients on the t

218 mprove outcome, and we recommend an exchange blood transfusion policy for all patients on the transpl

219 differences in rate of severe PPH, need for blood transfusion, postpartum hemoglobin, change in hemo

220 ariation exists in hospitals' intraoperative blood transfusion practices for older patients with sign

221 Hospital intraoperative blood transfusion practices may be a promising surgical

222 spitals, there was considerable variation in blood transfusion practices, and receipt of transfusion

223 both short- and long-term mortality, whereas blood transfusion predicted long-term mortality.

224 entified a priori, to compare rates of donor blood transfusion (primary outcome) and fetomaternal hae

225 pected, IDU (65.9% versus 17.8%; P < 0.001), blood transfusion prior to 1992 (22.3% versus 11.1%; P <

226 of ever injecting drugs and those who had a blood transfusion prior to 1992, a total of 1,886 subjec

227 traditional HCV risk factors such as IDU and blood transfusion prior to 1992.

228 Although injection drug use (IDU) and blood transfusions prior to 1992 are well-accepted risk

229 Presently, blood transfusion products (TPs) are composed of termina

230 ogeneic blood transfusions and an autologous blood transfusion program in colorectal cancer patients.

231 Postoperative complications, blood transfusions, prolonged length of stay (pLOS), rea

232 Donor blood transfusion rate was 3.5% in the control group ver

233 vaso-occlusive crisis and hemolytic events, blood transfusion rate, school attendance, and blood cou

234 effects and potentially immunosuppression in blood transfusion recipients.

235 irected therapy using fluids, inotropes, and blood transfusion reduced 30-day major complications in

236 molytic anemia, infection, tissue injury, or blood transfusion releases the endogenous damage-associa

237 reduced graft survival were: intraoperative blood transfusions, reoperation, human leukocyte antigen

238 Blood transfusion represents the first and most prescrib

239 increased mortality, organ injury, increased blood transfusion requirements, and reduced ICU ventilat

240 rdial fibrosis are associated with increased blood transfusion requirements, whereas left ventricular

241 by the pattern/severity of injury, including blood transfusion requirements.

242 ncluding proceedings of major conferences on blood transfusions), searching the Internet for hemovigi

243 the association of perioperative allogeneic blood transfusion, sepsis, and 5-year colon cancer disea

244 s, Ministry of Health websites, and National Blood Transfusion Services data for specific indicators

245 ile unintended, the foreign aid provided for blood transfusion services in sub-Saharan Africa has res

246 ialist); prompt neuro-imaging and an initial blood transfusion (simple followed immediately by an exc

247 Studies suggest that a restrictive blood transfusion strategy is equivalent to a liberal st

248 is needed to determine whether a restrictive blood transfusion strategy might improve PCI outcomes by

249 Potential triggers of blood transfusion such as baseline anemia, bleeding-vasc

250 Massive transfusion protocols for blood transfusion support are reviewed, including practi

251 Both cases required blood transfusion support to maintain their hemoglobin a

252 with regards to the hospital stay, volume of blood transfusion, surgery or mortality rate.

253 ry outcome included hospital stay, volume of blood transfusion, surgical intervention and mortality w

254 ances requiring transfusions, not due to the blood transfusions themselves.

255 harge, defined as the absence of rebleeding, blood transfusion, therapeutic intervention, 28 day read

256 OP], STOP II) have demonstrated that regular blood transfusion therapy (typically monthly) achieves p

257 nd silent cerebral infarcts includes regular blood transfusion therapy and in selected cases, hematop

258 trokes and new SCI despite receiving regular blood transfusion therapy for secondary stroke preventio

259 nial Doppler screening, coupled with regular blood transfusion therapy, has decreased the prevalence

260 Regular blood-transfusion therapy significantly reduced the inci

261 e lower among children who underwent regular blood-transfusion therapy than among those who received

262 y 10% increase in the rate of intraoperative blood transfusion, there was a 0.7% (95% CI: 0.3%-1.1%)

263 Although liberal blood transfusion thresholds have not been beneficial fo

264 servative fluid management, and conservative blood transfusion thresholds.

265 r liberal transfusion in which they received blood transfusion to maintain haemoglobin level at 100 g

266 s no evidence of virus transmission by whole-blood transfusion to naive monkeys based upon PCR analys

267 Variations in the delivery of operative blood transfusions to treat blood loss depend not only o

268 n with sickle cell anemia to receive regular blood transfusions (transfusion group) or standard care

269 on of Zika virus in semen, the potential for blood-transfusion transmission, mother-to-child transmis

270 Blood transfusion was administered to 195 women (2.5%).

271 Blood transfusion was administered to 27 (24%) patients

272 Among comparable patients, blood transfusion was associated with a lower risk of in

273 sity matching those with overlapping scores, blood transfusion was associated with a reduced risk of

274 In patients with postoperative MI, blood transfusion was associated with lower mortality, f

275 Blood transfusion was associated with mortality at 30 da

276 Transmission of GBV-C by blood transfusion was inversely related to HIV load.

277 Perioperative blood transfusion was shown to be a risk factor in the u

278 Blood transfusion was utilized in 2.2% of patients.

279 te chest syndrome, splenic sequestration, or blood transfusion) was less frequent with hydroxyurea (4

280 May 20, 2008, 413 children needing an urgent blood transfusion were admitted to Kilifi District Hospi

281 Erythropoiesis-stimulating agents and blood transfusion were also associated with VTE hospital

282 h weight, </= 1500 g) who had not received a blood transfusion were enrolled, with their mothers (n =

283 avenous fluids, vasopressors, inotropes, and blood transfusions were adjusted to reach central hemody

284 In unadjusted analysis, blood transfusions were associated with a 119% increased

285 ts who did and did not receive perioperative blood transfusions were compared using Cox regression an

286 sion (HR: 0.86, 95% CI: 0.60-1.23, P=0.672), blood transfusions were not associated with an increased

287 No blood transfusions were performed.

288 Hemodialysis, vasopressors, and blood transfusions were the interventions more likely to

289 ronous-major-procedure, inflow-occlusion and blood-transfusion were independent predictors of LCT-EOS

290 ple) and rs4374383 (in patients who received blood transfusions) were associated with fibrosis progre

291 strictive transfusion in which they received blood transfusion when haemoglobin level was lower than

292 erative and postoperative complications, and blood transfusion when undergoing a hysterectomy later i

293 lood negates the beneficial effects of fresh blood transfusion, which include reductions in infarct s

294 no studies have evaluated the association of blood transfusion with AKI in patients undergoing PCI.

295 cardiac tamponade; nonbypass surgery-related blood transfusion with preprocedure hemoglobin >/= 8 g/d

296 cent study showed that patients who received blood transfusion with threshold hemoglobin below 7 g/dl

297 erative and postoperative complications, and blood transfusion within 30 days of a hysterectomy.

298 he main exposure variable was receipt of any blood transfusion within 72 hours after surgery.

299 rs, organ space surgical site infection, and blood transfusion within 72 hours of surgery carried the

300 , and/or base deficit (>/=6 mEq/L), need for blood transfusion within the first 12 hrs, and an abbrev